FUSCO, ALFREDO
 Distribuzione geografica
Continente #
AS - Asia 13.749
NA - Nord America 12.763
EU - Europa 11.042
SA - Sud America 2.232
AF - Africa 340
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 40.150
Nazione #
US - Stati Uniti d'America 12.197
SG - Singapore 7.971
RU - Federazione Russa 5.473
CN - Cina 2.544
BR - Brasile 1.843
HK - Hong Kong 1.430
IT - Italia 1.156
VN - Vietnam 960
UA - Ucraina 766
DE - Germania 759
FI - Finlandia 685
IE - Irlanda 633
SE - Svezia 412
NL - Olanda 367
CA - Canada 351
GB - Regno Unito 317
IN - India 189
AR - Argentina 140
FR - Francia 133
MX - Messico 128
ZA - Sudafrica 116
BD - Bangladesh 112
EC - Ecuador 86
PL - Polonia 85
CI - Costa d'Avorio 74
ID - Indonesia 70
ES - Italia 65
JP - Giappone 64
IQ - Iraq 60
AT - Austria 51
TR - Turchia 50
VE - Venezuela 40
CO - Colombia 37
IR - Iran 33
LT - Lituania 31
KR - Corea 28
PY - Paraguay 27
CL - Cile 26
PK - Pakistan 24
UZ - Uzbekistan 24
AE - Emirati Arabi Uniti 23
KE - Kenya 22
MA - Marocco 22
CZ - Repubblica Ceca 19
SA - Arabia Saudita 18
IL - Israele 15
JO - Giordania 15
AZ - Azerbaigian 14
DO - Repubblica Dominicana 14
DZ - Algeria 14
BE - Belgio 13
PH - Filippine 13
EG - Egitto 12
KZ - Kazakistan 12
CR - Costa Rica 11
JM - Giamaica 11
OM - Oman 11
PE - Perù 11
AU - Australia 10
KG - Kirghizistan 10
RO - Romania 10
UY - Uruguay 10
HU - Ungheria 9
AL - Albania 8
BO - Bolivia 8
HN - Honduras 8
ET - Etiopia 7
GT - Guatemala 7
NI - Nicaragua 7
SN - Senegal 7
TH - Thailandia 7
TN - Tunisia 7
BB - Barbados 6
CH - Svizzera 6
GE - Georgia 6
LB - Libano 6
NP - Nepal 6
AO - Angola 5
BA - Bosnia-Erzegovina 5
CV - Capo Verde 5
GA - Gabon 5
MK - Macedonia 5
PA - Panama 5
PS - Palestinian Territory 5
BG - Bulgaria 4
IS - Islanda 4
MU - Mauritius 4
MY - Malesia 4
NA - Namibia 4
NG - Nigeria 4
PR - Porto Rico 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
BY - Bielorussia 3
GF - Guiana Francese 3
HR - Croazia 3
MD - Moldavia 3
MG - Madagascar 3
Totale 40.066
Città #
Singapore 3.403
Chandler 1.571
Hong Kong 1.428
Moscow 1.346
Jacksonville 831
Ashburn 816
Beijing 748
Princeton 530
Millbury 506
Santa Clara 503
Los Angeles 406
Nanjing 370
Ho Chi Minh City 338
Woodbridge 325
Amsterdam 320
Boston 273
Munich 252
Naples 248
Wilmington 242
Buffalo 236
Dallas 193
Ottawa 189
Hefei 184
Hanoi 173
New York 173
São Paulo 165
The Dalles 163
Houston 161
Napoli 148
Nanchang 141
Ann Arbor 132
Redondo Beach 131
Turku 116
Shenyang 93
Des Moines 82
Chicago 77
Hebei 77
Seattle 77
Dong Ket 76
Falls Church 76
Boardman 75
Tianjin 74
Norwalk 73
Brooklyn 72
Warsaw 72
Kronberg 65
Montreal 65
Frankfurt am Main 60
Jiaxing 60
Mexico City 60
Tokyo 59
Dublin 57
Chennai 56
Denver 54
Johannesburg 54
Rio de Janeiro 54
Changsha 51
Orem 51
Toronto 50
London 49
Stockholm 48
Helsinki 46
Nuremberg 46
Kunming 45
Belo Horizonte 43
Haiphong 43
Cagliari 42
Poplar 41
Atlanta 40
Biên Hòa 39
San Francisco 36
Washington 35
Phoenix 34
Da Nang 33
Aversa 31
Curitiba 31
Indiana 31
San Mateo 31
Augusta 30
Quito 30
Hải Dương 29
Manchester 28
Rome 28
Lawrence 25
Hangzhou 24
Guayaquil 23
Porto Alegre 23
Guarulhos 22
Baghdad 21
Charlotte 21
Guangzhou 21
Tashkent 21
Vienna 21
Brasília 20
Querétaro 20
Seoul 20
Nairobi 19
Shanghai 19
Elk Grove Village 18
Ninh Bình 18
Totale 19.726
Nome #
A ceRNA circuitry involving the long noncoding RNA Klhl14-AS, Pax8 and Bcl2 drives thyroid carcinogenesis 152
The complex CBX7-PRMT1 has a critical role in regulating E-cadherin gene expression and cell migration 151
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity 149
The Metallophosphoesterase-Domain-Containing Protein 2 (MPPED2) Gene Acts as Tumor Suppressor in Breast Cancer 148
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 147
PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration 140
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas 139
HMGA1 induces EZH2 overexpression in human B-cell lymphomas 138
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients 137
CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression 136
Upregulation of miR-21 by Ras in vivo and its role in tumor growth 135
HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. 134
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. 133
A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor 133
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells 133
Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. 132
UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. 131
New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma 131
Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes 130
Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. 129
UbcH10 expression in human lymphomas. 129
Wnt4 inhibits cell motility induced by oncogenic Ras 129
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. 128
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 128
The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. 128
High mobility group A1 protein modulates autophagy in cancer cells. 127
CBX7 is a tumor suppressor in mice and humans. 127
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 126
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 125
Increased BDNF promoter methylation in the wernicke area of suicide subjects. 125
PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells 125
Differential Expression of LncRNA in Bladder Cancer Development 124
Genetic ablation of homeodomain-interacting protein kinase 2 selectively induces apoptosis of cerebellar Purkinje cells during adulthood and generates an ataxic-like phenotype 124
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients 124
The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias 122
IFN-gamma gene expression is controlled by the architectural transcription factor HMGA1. 121
Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells. 121
HMGA1 overexpression is associated with a particular subset of human breast carcinomas 121
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. 120
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 119
High-mobility-group A1 (HMGA1) proteins down-regulate the expression of the recombination activating gene 2 (RAG2). 118
Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. 118
Translational regulation of a novel testis-specific RNF4 transcript. 118
TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters.. 118
CBX7 modulates the expression of genes critical for cancer progression. 118
miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene 118
High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. 117
From protein-protein interaction to E2 inhibitors leads: identification of peptide binding of UbcH10 117
Role of Dicer1 in thyroid cell proliferation and differentiation 117
HMGA1-pseudogene7 transgenic mice develop B cell lymphomas 117
Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice 116
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors 116
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells. 116
The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity 116
Hmga2 is necessary for Otx2-dependent exit of embryonic stem cells from the pluripotent ground state 115
FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. 114
Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. 114
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment 114
SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. 113
POZ-, AT-hook-, and Zinc Finger-containing Protein (PATZ) Interacts with Human Oncogene B Cell Lymphoma 6 (BCL6) and Is Required for Its Negative Autoregulation. 113
UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. 113
Mitogenic and dedifferentiating effect of the K-fgf/hst oncogene on rat thyroid PC clone 3 epithelial cells. 112
Roles of HMGA proteins in cancer. 112
Transformation of differentiated rat thyroid epithelial cells by viral and cellular oncogenes 112
UbcH10 is overexpressed in malignant breast carcinomas. 111
ONYX-015, an E1B gene-defective adenovirus,induces cell death in human anaplastic thyroid carcinoma cell lines. 111
NCOA4 inhibits initiation of DNA replication to maintain genome stability 111
Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice 111
Loss of one or two PATZ1 alleles has a critical role in the progression of thyroid carcinomas induced by the RET/PTC1 oncogene 111
TRANSCRIPTIONAL PROFILE OF KI-RAS-INDUCED TRANSFORMATION OF THYROID CELLS. 110
Human papilloma virus 16E7 oncogene does not cooperate with ret/ptc 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice 110
A mutated p53 gene alters thyroid cell differentiation 110
Hmga1 null mouse embryonic fibroblasts display downregulation of spindle assembly checkpoint gene expression associated to nuclear and karyotypic abnormalities 110
Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity 109
DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy 109
HMGA1-pseudogene expression is induced in human pituitary tumors 109
The "next-generation" knowledge of papillary thyroid carcinoma 109
The RET receptor: function in development and dysfunction in congenital malformation. 108
miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. 108
CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation 108
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 107
The lncRNA RMST is drastically downregulated in anaplastic thyroid carcinomas where exerts a tumor suppressor activity impairing epithelial-mesenchymal transition and stemness 106
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase 106
Critical role of the HMGA2 gene in pituitary adenomas. 106
Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. 106
Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. 106
HMGA1-pseudogene overexpression contributes to cancer progression 106
Double knock-out of Hmga1 and Hipk2 genes causes perinatal death associated to respiratory distress and thyroid abnormalities in mice 106
The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. 105
MicroRNA deregulation in human thyroid papillary carcinomas. 105
CBX7 role in tumor progression by functional proteomics approaches 105
RET activation and clinicopathologic features in poorly differentiated thyroid tumors. 104
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 104
CDH-16 gene expression in thyroid cell differentiation and transformation. 104
The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. 103
Molecular mechanisms of RET activation in human cancer 103
HMGA1 protein is a novel target of the ATM kinase. 103
HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas. 103
Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. 103
Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. 102
Totale 11.871
Categoria #
all - tutte 143.801
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.801


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.099 0 0 0 0 0 299 152 10 184 47 310 97
2021/20222.720 39 0 1 15 24 98 31 89 630 168 514 1.111
2022/20233.440 598 266 70 409 352 409 4 304 545 299 140 44
2023/20242.017 95 314 277 136 88 161 49 228 10 28 429 202
2024/202512.906 781 953 52 81 296 524 1.397 679 1.372 1.334 4.336 1.101
2025/202613.749 2.900 1.615 2.306 2.075 4.104 749 0 0 0 0 0 0
Totale 40.761